Fusion Pharmaceuticals Stock Short Ratio
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
Fusion Pharmaceuticals fundamentals help investors to digest information that contributes to Fusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharmaceuticals stock.
Fusion |
Fusion Pharmaceuticals Company Short Ratio Analysis
Fusion Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Fusion Pharmaceuticals Short Ratio | 6.22 X |
Most of Fusion Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fusion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, Fusion Pharmaceuticals has a Short Ratio of 6.22 times. This is 59.49% higher than that of the Biotechnology sector and 16.06% lower than that of the Health Care industry. The short ratio for all United States stocks is 55.5% lower than that of the firm.
Fusion Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fusion Pharmaceuticals by comparing valuation metrics of similar companies.Fusion Pharmaceuticals is currently under evaluation in short ratio category among its peers.
Fusion Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X | |||
| Revenue | 2.07 M | |||
| Gross Profit | (57.43 M) | |||
| EBITDA | (97.89 M) | |||
| Net Income | (94.9 M) | |||
| Cash And Equivalents | 198.42 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 50.33 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 17.89 X | |||
| Book Value Per Share | 2.85 X | |||
| Cash Flow From Operations | (81.8 M) | |||
| Short Ratio | 6.22 X | |||
| Earnings Per Share | (1.40) X | |||
| Target Price | 21.14 | |||
| Number Of Employees | 101 | |||
| Beta | -0.69 | |||
| Market Capitalization | 1.83 B | |||
| Total Asset | 285.84 M | |||
| Retained Earnings | (376.76 M) | |||
| Working Capital | 227.18 M | |||
| Net Asset | 285.84 M |
About Fusion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Fusion Stock
| 0.49 | PG | Procter Gamble | PairCorr |
| 0.41 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.34 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.33 | VZ | Verizon Communications Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Fusion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fusion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fusion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fusion Pharmaceuticals to buy it.
The correlation of Fusion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fusion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fusion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fusion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |